Brain Biotechnology Research and Information Network AG

BRAIN Biotechnology Research and Information Network AG is a Germany-based industrial biotechnology company, which is active in two segments: The BioSciences segment comprises research and development activities related to replacing classical chemical and industrial processes with biotechnology processes, and the BioIndustrial segment focuses on the development of own products for both companies and consumers. The Company develops drugs, bioactive natural compounds and enzymes for customers in the chemical and pharmaceutical industries, as well as in the food and cosmetics industries. It offers research and development collaboration, as well as strategic partnerships and exclusive licensing agreements through all phases of enzyme and biological compound discovery to application development and production. The Company's product portfolio includes EvoSolution, METAGENOME, BRAINzyme, LIL, ABEL, CompActives and BioCompActives.
  • TickerBNN
  • ISINDE0005203947
  • SectorChemicals
  • CountryGermany

Analysts

Thomas J. Schiessle

H1/18-19 mit starkem Konsolidierungsrückenwind

H1 profitierte stark von positiven Konsolidierungseffekten (seit März 2018: Biocatalysts Ltd.). Die Investoren warten auf belastbare Nachweise für die Skalierungsfähigkeit des Geschäftsmodells im B2B-Segment „BioIndustrials“ („BI“)). Im H1/18-19 verbesserte sich das EPS auf € -0,23 (H1/18: € -0,26). Cash-Bestand € 18,5 Mio. (30.09.18: € 25,5 Mio.). Das originäre und das zugekaufte Geschäft wuchsen – der Konzernumsatz stieg um 73 % ggü Vj. (GL: +60,7 % auf € 19,8 Mio.). Das adj. EBITDA: € –1,7 Mio. (Vj: € -2,8 Mio.).

Thomas J. Schiessle

H1/18-19 mit starkem Konsolidierungsrückenwind

H1 profitierte stark von positiven Konsolidierungseffekten (seit März 2018: Biocatalysts Ltd.). Die Investoren warten auf belastbare Nachweise für die Skalierungsfähigkeit des Geschäftsmodells im B2B-Segment „BioIndustrials“ („BI“)). Im H1/18-19 verbesserte sich das EPS auf € -0,23 (H1/18: € -0,26). Cash-Bestand € 18,5 Mio. (30.09.18: € 25,5 Mio.). Das originäre und das zugekaufte Geschäft wuchsen – der Konzernumsatz stieg um 73 % ggü Vj. (GL: +60,7 % auf € 19,8 Mio.). Das adj. EBITDA: € –1,7 Mio. (Vj: € -2,8 Mio.).

Martial Descoutures ...
  • Pierre Corby

BRAIN AG : Brisk top line growth for Q1 2018-19

>Q1 2018-19: revenues of € 9.4m (+79%) - BRAIN has made a good start to FY 2018-19. Over the first three months (from 1 October, 2018 to 31 December, 2018), the group’s operating performance amounted to € 9.9m (vs € 6.0m), up 64%, while group revenues rose 79% to € 9.4m (vs € 5.3m). At the operating level, adjusted EBITDA reached € 0m compared to a loss of € 1.3m for the same period last year. The BioIndustrial (product business) segment generated revenues of € 6.5m (...

Martial Descoutures ...
  • Pierre Corby

BRAIN AG : Une bonne croissance topline pour le T1 2018/2019

>T1 2018/2019 : revenus de 9.4 M€ (+79%) - BRAIN commence bien l’exercice 2018/2019. Sur les 3 premiers mois (du 1er octobre 2018 au 31 décembre 2018), « Operating performance » s’élève à 9.9 M€ (vs 6.0 M€) en progression de 64%, le « Group revenues » à 9.4 M€ (vs 5.3 M€) progresse de 79%. Au niveau opérationnel, l’EBITDA ajusté atteint 0 M€ contre une perte de -1.3 M€ sur la même période l’année précédente. Le segment BioIndustrial (product business) a engrangé des ...

Thomas J. Schiessle

Gj. 2018-19 – „die Mühe der Ebene“

Expansionsrichtung und -Geschwindigkeit bleiben u.E. auch in den kommenden Quartalen wenig verändert. Eine Guidance für Gj.18-19 wurde im nun veröffentlichten GB2017-18 publiziert. Diese Planung trifft auf  unsere Erwartung und die EQUI.TS-Schätzung.

Thomas J. Schiessle

BRAIN-Drain - neuer Zielkurs

Auch die jüngsten Kennzahlen dokumentieren u.E. die geringe Visibilität der operativen Aussichten (Schätzung und Kursziel angepasst). Die strategischen Trends dagegen entwickeln sich positiv. Die Veränderungen im Vorstand sind positiv und für die künftige Entwicklung u.E. entscheidend. Die Skalierungsfähigkeit des Geschäftsmodells im B2B-Segment „BioIndustrials“ ist zentraler Wachstumsbaustein. Beschleunigter Marktzugang muss erreicht werden. Die Umsatz-Guidance für 2018 („zweistelliges Wachstum“ ggü. Vj.) - i.W. durch Zukäufe (Biocatalytics Ltd.) - wurde erreicht. Eine konkrete Guidance für G...

1 director bought

A director at Biotechnology Research And Information Network bought 5,000 shares at 10.960EUR and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under li...

Alain William ...
  • Baptiste Lebacq
  • Charles Lepetitpas
  • Christophe Chaput
  • Fatma Agnès Hamdani
  • Geoffroy Michalet
  • Hela Zarrouk
  • Jeremy Garnier
  • Jerôme Bodin
  • Martial Descoutures
  • Nicolas David
  • Nicolas Thorez
  • Olfa Taamallah
  • Olivier Lebrun
  • Oussema Denguir
  • Pierre Corby
  • Rémi Adam
  • Salma Bouraoui
  • Stephane Houri
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 03/01/2019

...

Alain William ...
  • Baptiste Lebacq
  • Charles Lepetitpas
  • Christophe Chaput
  • Fatma Agnès Hamdani
  • Geoffroy Michalet
  • Hela Zarrouk
  • Jeremy Garnier
  • Jerôme Bodin
  • Martial Descoutures
  • Nicolas David
  • Nicolas Thorez
  • Olfa Taamallah
  • Olivier Lebrun
  • Oussema Denguir
  • Pierre Corby
  • Rémi Adam
  • Salma Bouraoui
  • Stephane Houri
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 01/03/2019

...

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Expert Corporate Governance Service (ECGS)

Brain - March, 07th 2019

General: B.R.A.I.N. Biotechnology Research and Information Network AG is one of Europe's leading technology companies in the field of industrial biotechnology, the core discipline of Bioeconomy. The Company identifies previously untapped, efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. BRAIN's business model is based on two pillars – BioScience and BioIndustrial. BioScience comprises the Company's frequently exclusive collaboration business with industrial partners. BioIndustrial comprises the development ...

Expert Corporate Governance Service (ECGS)

Proxy Report - 08/03/2018

General: B.R.A.I.N. Biotechnology Research and Information Network AG is one of Europe's leading technology companies in the field of industrial biotechnology, the core discipline of Bioeconomy. The Company identifies previously untapped, efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. BRAIN's business model is based on two pillars – BioScience and BioIndustrial. BioScience comprises its frequently exclusive collaboration business with industrial partners. BioIndustrial comprises the development and commer...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch